Michael Earl, director, pharmaceutical services at Owen Mumford, examines the benefits that patients are set to receive as the connected drug delivery devices market grows.
Key insights:
- With digitalisation, devices can support the patient during the injection procedure, by providing feedback to facilitate the rotation of injection sites, confirmation of drug delivery and injection reminders.
- Better collection and application of patient data will streamline treatment for patients and allow for patient groups to receive more personalised care.
- The number of device configurations set to be available will allow pharmaceutical companies to choose appropriate features for the needs of different patient groups.
If used intelligently, data collected by connected medical products has vast potential for every stakeholder in the healthcare system. The expansion of the connected drug delivery market is set to create an improved treatment experience for patients in the coming years; some of these benefits to patients are self-evident but others in the early stages are not yet mainstream. Various digital features from connected drug delivery devices are set to make the lives of patients easier and ensure the actual injection process is as smooth as possible. Simplifying the process of using these devices along with human factors based product design, will help to make connected drug delivery a more inclusive experience, potentially encouraging more patient groups to adopt it as a method of therapy.